From the Research
Total Circumferential Hyperthermic Perfusion (TCHP) and Port Requirement
- The provided studies do not directly address the need for a port in Total Circumferential Hyperthermic Perfusion (TCHP) 1, 2, 3, 4, 5.
- However, studies 1 and 2 discuss the use of totally implantable venous access ports in oncology patients, highlighting their value in long-term intravenous treatment and the management of complications associated with their use.
- Study 5 mentions the use of hyperthermic therapy, including total body hyperthermia and continuous hyperthermic peritoneal perfusion, as an adjuvant therapy in advanced gastric cancer, but does not specifically address the need for a port in TCHP.
- Studies 3 and 4 focus on the safety and efficacy of neoadjuvant TCHP regimens in patients with HER2-positive breast cancer, but do not provide information on the requirement of a port for TCHP.
Complications and Management
- The use of ports in oncology patients can be associated with complications such as venous thrombosis, port infection, extravasation, and catheter leakages 1, 2.
- Study 2 identifies risk factors for port infection, including male sex, low body mass index, and the purpose of use, and suggests strategies for management and prevention.
- The management of complications related to port use is crucial to reduce the risk of infection and other adverse events 1, 2.